The Campaign for Sustainable Rx Pricing
A coalition of organizations working on market-based solutions to drug pricing.
Based in DC
🤖
AI Overview
With $2.5M in lobbying spend across 31 quarterly filings, The Campaign for Sustainable Rx Pricing is a significant lobbying presence. They deploy 30 individual lobbyists
$2.5M
Total Lobbying Spend
31
Quarterly Filings
1
Lobbying Firms Used
30
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $320K |
| 2019 | $320K |
| 2020 | $520K |
| 2021 | $330K |
| 2022 | $220K |
| 2023 | $200K |
| 2024 | $180K |
| 2025 | $360K |
Lobbying Firms
MEHLMAN CONSULTING, INC.
What They Lobby For
- Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017. Medicare Part D Biosimilars. H.R 1892 - The Bipartisan Budget Act of 2018, Omnibus
- Prescription drug pricing. Medicare Part D Biosimilars. H.R. 1892 - The Bipartisan Budget Act of 2018, Omnibus
- Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D Biosimilars.
- H.R. 1892 - The Bipartisan Budget Act of 2018, Omnibus
- Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017. Medicare Part D Biosimilars.
- Prescription drug pricing. Medicare Part D Biosimilars.
- Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017. Medicare Part D Biosimilars. H.R.6 - SUPPORT for Patients and Communities Act. S. 3120 - HEAL Act of 2018. S. 2553: Know the Lowest Price Act of 2018. S. 2554: Patient Right to Know Drug Prices Act.
- Prescription drug pricing. Medicare Part D Biosimilars. H.R.6 - SUPPORT for Patients and Communities Act. S. 2553: Know the Lowest Price Act of 2018. S. 2554: Patient Right to Know Drug Prices Act.
- Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D Biosimilars. H.R.6 - SUPPORT for Patients and Communities Act. S. 2553: Know the Lowest Price Act of 2018. S. 2554: Patient Right to Know Drug Prices Act.
- Prescription drug pricing. S. 340 - CREATES Act of 2019. H.R. 985 - FAST Generics Act of 2019. H.R. 1520 - Purple Book Continuity Act of 2019. H.R. 1503 - Orange Book Transparency Act of 2019.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.